Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: A population-based cohort study - Kim, S C; Schneeweiss, S; Glynn, R J (Ann Rheum Dis, 2015)
et al.